Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Esperion Therapeutics, Inc.
< Previous
1
2
Next >
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
December 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
November 13, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
November 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
June 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
June 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
June 15, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
June 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
June 05, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
June 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
May 25, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Jefferies Healthcare Conference
May 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 12, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Reports First Quarter 2023 Financial Results
May 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
May 04, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in JMP Securities Life Sciences Conference
May 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
April 27, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
April 25, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
April 19, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ESPR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.